English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The goal of this study is a technology analysis of a revolution for themanagement of valvular heart diseases given by new technological system basedon transcatheter artificial aortic valve, a delivery catheter and a loadingsystem for the treatment of aortic stenosis (a narrowing of the aortic valvebecause of calcium build up that restricts blood flow to aorta, the body's mainartery) in patients at intermediate and greater risk for surgical therapy. Inparticular, this study analyzes the technological trajectories of newtechnology of transcatheter aortic valve implantation (TAVI) in relation to theestablished technology of surgical aortic valve replacement (SAVR). To explorethe emerging technology of TAVI for valvular heart diseases, a model is appliedto show how new TAVI technology is substituting established technologies ofSAVR to revolutionize the management of aortic stenosis in cardiology.Statistical analyses reveal the sharp increase of the scientific production ofTAVI that has a coefficient of growth as function of time equal to 0.40(p<.001) versus a coefficient for SAVR technology of 0.10 (p<.001). Thisfinding suggests a technological forecasting that TAVI will be the dominanttechnology for the treatment of patients with valvular heart diseases. Overall,then, this study shows that new technology of transcatheter aortic valveimplantation (TAVI) introduced in 2002 is growing in terms of scientific,inventive and innovative activity to revolutionize the management of aorticstenosis in cardiology worldwide.

A new technological system to revolutionize the management of valvular  heart diseases: transcatheter aortic valve for the treatment of aortic  stenosis